Clinical Trial Update: Sorafenib for Hepatopulmonary Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial of sorafenib for hepatopulmonary syndrome was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatopulmonary Syndrome

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: University of Pennsylvania | Conditions: Hepatopulmonary Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2019-04-25